Cartesian Therapeutics, Inc. (RNAC)
After hours:
| Previous close | 20.90 |
| Open | 20.98 |
| Bid | 20.86 x 100 |
| Ask | 21.23 x 200 |
| Day's range | 20.72 - 21.74 |
| 52-week range | 11.66 - 42.60 |
| Volume | |
| Avg. volume | 52,580 |
| Market cap | 373.909M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 51.00 |
Business WireCartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
GAITHERSBURG, Md., April 22, 2024--Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that recently reported twelve-month follow-up data from its Phase 2a trial of Descartes-08 in patients with generalized myasthenia gravis will be featured during an oral presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11, 2024 i
Business WireCartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
GAITHERSBURG, Md., April 04, 2024--Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 3:00 p.m. ET.
Business WireCartesian Therapeutics Announces New Employment Inducement Grants
GAITHERSBURG, Md., April 04, 2024--Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On April 1, 2024, the Company issued to each of these employees an option to purchase shares of the Company’s common stock with an exercise price of $0.5601, the closing trading price of the Company’s common stock on th
